- Home
- AVTX vs ABP Comparison
AVTX vs ABP Comparison
Compare AVTX & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- ABP
- Stock Information
- Founded
- AVTX 2011
- ABP 2004
- Country
- AVTX United States
- ABP United States
- Employees
- AVTX N/A
- ABP N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- ABP Health Care
- Exchange
- AVTX Nasdaq
- ABP Nasdaq
- Market Cap
- AVTX 88.4M
- ABP 76.2M
- IPO Year
- AVTX 2015
- ABP N/A
- Fundamental
- Price
- AVTX $8.44
- ABP $0.84
- Analyst Decision
- AVTX Strong Buy
- ABP
- Analyst Count
- AVTX 4
- ABP 0
- Target Price
- AVTX $33.00
- ABP N/A
- AVG Volume (30 Days)
- AVTX 36.6K
- ABP 38.3K
- Earning Date
- AVTX 03-28-2025
- ABP 02-28-2025
- Dividend Yield
- AVTX N/A
- ABP N/A
- EPS Growth
- AVTX N/A
- ABP N/A
- EPS
- AVTX N/A
- ABP N/A
- Revenue
- AVTX $820,000.00
- ABP $230,000.00
- Revenue This Year
- AVTX N/A
- ABP N/A
- Revenue Next Year
- AVTX N/A
- ABP N/A
- P/E Ratio
- AVTX N/A
- ABP N/A
- Revenue Growth
- AVTX N/A
- ABP N/A
- 52 Week Low
- AVTX $4.24
- ABP $0.80
- 52 Week High
- AVTX $34.46
- ABP $13.00
- Technical
- Relative Strength Index (RSI)
- AVTX 57.77
- ABP N/A
- Support Level
- AVTX $6.81
- ABP N/A
- Resistance Level
- AVTX $8.00
- ABP N/A
- Average True Range (ATR)
- AVTX 0.56
- ABP 0.00
- MACD
- AVTX 0.03
- ABP 0.00
- Stochastic Oscillator
- AVTX 81.99
- ABP 0.00
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions.